PRAX

Praxis Precision Medicines, Inc. PRAX

NasdaqMid CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-83.72M

Quarter to Jun 30

Free cash flow

$-77.79M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$11.28B total
Jupiter Topco LLC
$1.15B--
FMR LLC
$775.68M+7.2%
BlackRock, Inc.
$767.53M-1.4%
PERCEPTIVE ADVISORS LLC
$681.63M0.0%
BAKER BROS. ADVISORS LP
$586.95M0.0%
Orbis Allan Gray Ltd
$512.16M-38.1%
VANGUARD PORTFOLIO MANAGEMENT LLC
$447.01M+76.4%
VANGUARD CAPITAL MANAGEMENT LLC
$413.57M+1.1%
STATE STREET CORP
$343.66M+16.1%
ADAGE CAPITAL PARTNERS GP, L.L.C.
$339.97M+24.5%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$322.52M0.0%
DRIEHAUS CAPITAL MANAGEMENT LLC
$321.08M+1.0%
PRICE T ROWE ASSOCIATES INC /MD/
$315.71M+49.5%
MORGAN STANLEY
$285.95M+2.5%
GEODE CAPITAL MANAGEMENT, LLC
$250.48M+14.9%
Cormorant Asset Management, LP
$214.27M-27.7%
GOLDMAN SACHS GROUP INC
$183.74M-22.8%
BANK OF AMERICA CORP /DE/
$183.11M+2.3%
Invesco Ltd.
$179.97M+775.5%
Hood River Capital Management LLC
$142.34M+18.6%
NORGES BANK
$116.16M--
FRANKLIN RESOURCES INC
$109.52M+18.5%
Pictet Asset Management Holding SA
$98.04M+1.8%
Polar Capital Holdings Plc
$93.45MNew
Vivo Capital, LLC
$90.77M-20.0%
See all 311 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/PRAX

Earnings Per Share

13fpro.ai/company/PRAX

Loading ratio trend…

PRAX key financials by period

Reported revenue, net income and operating margin by fiscal year, from Praxis Precision Medicines, Inc.'s annual filings on SEC EDGAR.

Praxis Precision Medicines, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2024$8.6M$-182.8M—
FY 2023$2.4M$-123.3M—
Source: PRAX filings on SEC EDGAR →

PRAX insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

Congress trading in PRAX

2 transactions in PRAX reported by 1 member of Congress under the STOCK Act, most recent trade Sep 29, 2026. Reported transactions, not recommendations.

All Congress stock trades →

About Praxis Precision Medicines, Inc. (PRAX): stock profile, AI score and financials

Praxis Precision Medicines, Inc. (PRAX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. PRAX is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Praxis Precision Medicines, Inc. reports net income of $-83.7M, free cash flow of $-77.8M. Top institutional holders of PRAX by reported 13-F value include Jupiter Topco, FMR, BlackRock, based on the most recent SEC filings. PRAX trades on the Nasdaq exchange and files with the SEC under CIK 1689548. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PRAX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Praxis Precision Medicines, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1689548 →